BPL Ltd
Pharmaceuticals & Biotechnology | Small Cap
BPL Ltd, operating in the consumer durables sector, demonstrates a mixed financial performance. The company shows strong solvency and profitability, driven by a healthy equity position and solid margins. Revenue and asset growth are positive, indicating market expansion. However, liquidity is a concern, with low current and cash ratios. Efficiency is also mixed, with good inventory management but challenges in asset utilization and receivable collection. While interest coverage is adequate, the absence of dividend coverage is a notable weakness. Overall, BPL showcases potential with its growth and profitability, but needs to address liquidity and efficiency to ensure sustainable financial health. Recent capital expenditure may be a cause for concern.
Latest Report
View AllThe Latest Reports Are Not Available at the Moment. We’ll Notify You Once They’re Available.
Latest News
View AllThe Latest News Is Not Available at the Moment. We’ll Notify You Once It’s Available.
- Valuation MetricsNeutral
- Market Metrics
- Stock Reports
- Stock News
- Growth Ratio6.00
- Financial Ratio2.40
- Profitability Ratio9.20
- Efficiency Ratio5.00
- Coverage Ratio6.80
- Solvency Ratio10.00
- Liquidity Ratio2.40
- Peer Assessment
- Management AssessmentBalanced
- Risk AssessmentBalanced
- 1 HourNeutral
- 2 HoursNeutral
- 4 HoursNeutral
- 1 DayNeutral
- 1 WeekNeutral
- 1 MonthNeutral
BPL Ltd, operating in the consumer durables sector, demonstrates a mixed financial performance. The company shows strong solvency and profitability, driven by a healthy equity position and solid margins. Revenue and asset growth are positive, indicating market expansion. However, liquidity is a concern, with low current and cash ratios. Efficiency is also mixed, with good inventory management but challenges in asset utilization and receivable collection. While interest coverage is adequate, the absence of dividend coverage is a notable weakness. Overall, BPL showcases potential with its growth and profitability, but needs to address liquidity and efficiency to ensure sustainable financial health. Recent capital expenditure may be a cause for concern.
Overall Valuation Score
P/E RATIO (TTM)
-18.28
Industry Median
28.93
Small Cap Median
26.92
P/E RATIO
-31.34
P/B RATIO
1.11
Industry Median
3.18
Small Cap Median
2.63
P/S RATIO
3.47
Industry Median
3.41
Small Cap Median
2.40
Others
PEG RATIO
0.00
EV/EBITDA RATIO
-119.17
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹54.84 as on Jun 18, 2026.
Unlock Live Chart
Please login to view interactive real-time technical charts powered by TradingView.
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
0.00
Today's Low
0.00
Today's High
The company demonstrates strong revenue and asset growth, along with a significant increase in operating profit. However, earnings per share and net income growth are negative, indicating potential issues with profitability despite revenue gains. Overall, the company is expanding its operations, but profitability needs to catch up with revenue growth. The company has potential to grow, but profitability is a major concern.
| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 36.52 | 27.21 | 17.96 | -0.31 | |
| Operating Profit Growth Rate | 4446.15 | 142.3 | -12.57 | -138.5 | |
| Earnings Per Share (EPS) Growth | -61.13 | 168.93 | -98.19 | -3600 | |
| Asset Growth Rate | 11.73 | 2.86 | -0.56 | 16.44 | |
| Net Income Growth Rate | -60.93 | 165.02 | -99.25 | -8650 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
The company's financial ratios indicate a mixed performance. While cash earnings per share are positive, adjusted earnings per share and book value per share are relatively low. The company is not paying dividends, and capital expenditures are high, suggesting significant investments. Overall, the company is making investments, but returns are not yet reflected in earnings. Recent capital expenditure may be a cause for concern.
| Financial Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Adjusted Earnings Per Share (Adjusted EPS) | 2.65 | 1.03 | 2.74 | -18.76 | -1.74 |
| Cash Earnings Per Share (Cash EPS) | 2.99 | 1.38 | 3.14 | 0.49 | -1.25 |
| Book Value Per Share | 33.97 | 48.16 | 50.92 | 50.89 | 49.19 |
| Dividend Per Share (DPS) | 0 | 0 | 0 | 0 | 0 |
| Capital Expenditures (CapEx) | 0.2 | 4.2 | 6 | 47.9 | 0.3 |
Adjusted Earnings Per Share (Adjusted EPS)
Cash Earnings Per Share (Cash EPS)
Book Value Per Share
Dividend Per Share (DPS)
Capital Expenditures (CapEx)
The company's profitability ratios are generally strong, with good gross profit, ROCE, ROE, and operating and net margins. However, return on assets is relatively low, indicating potential inefficiencies in asset utilization. Overall, the company is profitable, but there is room to improve asset management. The company is in a very good shape in terms of profitability. The company can focus on improving its asset management.
| Profitability Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Gross Profit Margin | -4.03 | 8.08 | 18.56 | 13.06 | -9.27 |
| Return on Capital Employed (ROCE) | 5.62 | 3.86 | 4.35 | 4.91 | -1.22 |
| Return on Equity (ROE) | 7.8 | 2.14 | 5.37 | 0.04 | -3.55 |
| Return on Assets (ROA) | 0.02 | 0.99 | 2.32 | 2.04 | -0.68 |
| Operating Margin | 0.34 | 11.32 | 21.56 | 15.98 | -6.17 |
| Net Margin | 33.86 | 9.69 | 20.19 | 0.13 | -10.94 |
Gross Profit Margin
Return on Capital Employed (ROCE)
Return on Equity (ROE)
Return on Assets (ROA)
Operating Margin
Net Margin
The company's efficiency ratios present a mixed picture. Inventory management is strong, but fixed asset and capital turnover are low, indicating underutilization of assets. Receivable collection is also slow, suggesting potential issues with credit policies. Overall, there is room to improve asset utilization and working capital management. The company can focus on improving the turnover ratio to increase efficiency.
| Efficiency Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Fixed Asset Turnover Ratio | 0.69 | 0.9 | 1.11 | 1.28 | 1.32 |
| Inventory Turnover Ratio | 6.63 | 9.6 | 12.02 | 13.63 | 12.19 |
| Receivables Turnover Ratio | 2.93 | 3.87 | 3.8 | 3.48 | 3.19 |
| Days Sales in Inventory Ratio | 55.05 | 38.02 | 30.37 | 26.78 | 29.94 |
| Receivable Days | 124.53 | 94.32 | 96.05 | 104.89 | 114.42 |
| Capital Turnover Ratio | 0.23 | 0.22 | 0.26 | 0.31 | 0.23 |
Fixed Asset Turnover Ratio
Inventory Turnover Ratio
Receivables Turnover Ratio
Days Sales in Inventory Ratio
Receivable Days
Capital Turnover Ratio
The company exhibits strong interest coverage, indicating a healthy ability to meet its interest obligations. However, the lack of equity dividend coverage is a notable weakness, suggesting that the company is not providing returns to its equity holders. The company is stable in terms of interest coverage. But the company is not providing returns to its equity holders.
| Coverage Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Interest Coverage Ratio | 5.4 | 9.12 | 22.09 | 1.07 | -3.8 |
| Equity Dividend Coverage Ratio |
Interest Coverage Ratio
Equity Dividend Coverage Ratio
The company's solvency position is very strong, characterized by low debt levels and a high proportion of equity. This indicates a stable financial structure and reduced risk of financial distress. The company has a solid foundation for future growth and stability. This implies that the company is not taking on too much debt. Future expansion of the company using debt might be difficult.
| Solvency Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Debt Ratio | 0.11 | 0.08 | 0.08 | 0.08 | 0.28 |
| Debt to Equity Ratio | 0.12 | 0.09 | 0.09 | 0.09 | 0.39 |
| Equity Ratio | 0.89 | 0.92 | 0.92 | 0.92 | 0.72 |
| Debt To Asset Ratio | 0.04 | 0.04 | 0.04 | 0.04 | 0.13 |
Debt Ratio
Debt to Equity Ratio
Equity Ratio
Debt To Asset Ratio
The company's liquidity position reflects potential challenges in meeting its short-term obligations. While there is adequate operating cash flow, the low current and quick ratios suggest limited liquid assets. This indicates a need for improved working capital management to ensure smoother operations. Depending on short-term obligations, it can cause significant concern to the company. Despite these challenges, the company is able to generate some cash from its operation.
| Liquidity Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Current Ratio | 0.32 | 0.32 | 0.35 | 0.35 | 0.59 |
| Quick Ratio | 0.31 | 0.3 | 0.33 | 0.33 | 0.56 |
| Cash Ratio | 0 | 0.01 | 0.03 | 0.01 | 0.01 |
| Operating Cash Flow Ratio | 0 | 0.02 | 0.02 | 0.03 | -0.23 |
Current Ratio
Quick Ratio
Cash Ratio
Operating Cash Flow Ratio
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Medico Remedies Ltd | 6.61 | 37.70 | Overvalued | 17.00 | 1.58 | 13.00 |
| 2 | SMS Lifesciences India Ltd | 6.59 | 21.78 | Neutral | 45.00 | 70.68 | 19.00 |
| 3 | Infinium Pharmachem Ltd | 6.42 | 26.49 | Neutral | 22.00 | 6.43 | 14.00 |
| 4 | Aarey Drugs & Pharmaceuticals Ltd | 5.73 | 58.49 | Neutral | 7.00 | 1.40 | 4.00 |
| 5 | Albert David Ltd | 5.63 | -272.76 | Neutral | 5.00 | -2.62 | -1.00 |
| 6 | BPL Ltd | 5.46 | -31.34 | Neutral | -4.82 | -3.00 | -8.55 |
| 7 | Zim Laboratories Ltd | 5.41 | 41.96 | Neutral | 30.00 | 1.11 | 6.00 |
| 8 | Quest Laboratories Ltd | 5.27 | 11.86 | Neutral | 18.00 | 9.16 | 15.00 |
| 9 | Sotac Pharmaceuticals Ltd | 5.27 | 21.26 | Neutral | 18.00 | 4.45 | 6.00 |
| 10 | Lyka Labs Ltd | 4.77 | -24.93 | Neutral | -4.00 | -9.05 | -10.00 |
| 11 | Krebs Biochemicals & Industries Ltd | 4.16 | -5.14 | Highly Undervalued | -4.00 | -12.49 | -4.00 |
| 12 | Nectar Lifescience Ltd | 3.83 | -2.67 | Neutral | -59.00 | -2.95 | -293.00 |
Management effectiveness presents a mixed picture. The company shows positive trends in sales growth but experiences volatility in net profit. Although sales have grown, profitability is inconsistent. Capital efficiency, as indicated by ROCE, has improved recently. Promoter holding remains stable, demonstrating continued alignment with shareholder interests. Debt management appears to be under control with lower borrowings, but there are fluctuations in working capital management. Overall, management demonstrates strengths in revenue generation and operational efficiency but needs to address profit volatility and working capital management for sustained financial health.
| Category | Metric | Value | Assessment |
|---|---|---|---|
| PROS | Sales Growth | 17.96% (Mar 2025) | Revenue expansion is strong. |
| Operating Profit Margin | 15.51% (Mar 2025) | Operational efficiency is improving. | |
| Promoter Holding | 63.13% | Confidence and alignment with shareholders. | |
| CONS | Net Profit Volatility | -18 (Mar 2025) | Financial performance is volatile. |
| Working Capital Days | -675.13 (Mar 2025) | Operational cycles are inefficient. |
Financial Performance & Growth
The company exhibits inconsistent financial performance. While sales growth is positive, profit growth is volatile. This inconsistency raises concerns about the sustainability of earnings.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Sales Growth (%) | 36.52% | 27.21% | 17.96% | 17.96% |
| OPM (%) | 0.34% | 11.32% | 21.56% | 15.51% |
| Net Profit (Rs) | 12.95 | 5.06 | 13.41 | 0.09 |
Capital Efficiency & Returns
Capital efficiency shows mixed results. While Return on Capital Employed (ROCE) has improved, other metrics such as Return on Equity (ROE) are not consistently strong. This suggests that while capital is being used more productively recently, the overall returns to shareholders could be better.
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| ROCE % | 3.86% | 4.35% | 16.99% |
Financial Health & Prudence
Financial health indicators present a mixed view. Debt management appears to be under control with lower borrowings. However, the dividend payout is zero, which might not be favorable for investors seeking regular income.
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Borrowings (Rs Cr) | 22.86 | 30.09 | 8.05 |
| Dividend Payout % | -0.00% | -0.00% | -0.00% |
Strategic & Operational Indicators
Operational efficiency, as indicated by working capital management, shows mixed signals. Debtor days and inventory days fluctuate, while the cash conversion cycle is negative, suggesting efficient working capital management. However, the variability in these metrics indicates potential inefficiencies in operational cycles.
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Debtor Days | 97.02 | 117.53 | 111.28 |
| Inventory Days | 52.24 | 54.25 | 48.14 |
| Cash Conversion Cycle | -82.09 | -39.71 | -47.38 |
The risk assessment for BPL Ltd. indicates a moderate level of risk, primarily due to inconsistent financial performance and operational inefficiencies. While the company has shown improvement in sales growth and capital efficiency, the volatility in net profit and working capital management raises concerns. The stable promoter holding and low debt levels are positive signs, but the absence of dividend payouts and fluctuations in operational cycles suggest potential areas of instability.
Off-balance sheet exposure quantification
There is no specific data available to quantify off-balance sheet exposures.
Contingent liability evaluation
There is no specific data available to evaluate contingent liabilities.
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 1 Hour Timeframe
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 2 Hours Timeframe
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 4 Hours Timeframe
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 1 Day Timeframe
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 1 Week Timeframe
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 1 Month Timeframe